HomeAbout

TL;DR CNBC


Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs - TL;DR CNBC

Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

Publishing timestamp: 2024-10-31 14:21:55


Summary

Bristol Myers Squibb reported third-quarter earnings and revenue that exceeded expectations, driven by strong sales of its blood thinner Eliquis and other key drugs. The pharmaceutical giant also raised its full-year revenue and adjusted earnings forecast, leading to a more positive outlook for the company.


Sentiment: POSITIVE

Tickers: BMYPFE

Keywords: business newsearningsbreaking newsbreaking news: earningsbusinesspfizer incpharmaceuticalsbreaking news: businessbristol-myers squibb cohealth care industrybiotech and pharmaceuticalsjoe bidenbiotechnology

Source: https://www.cnbc.com/2024/10/31/bristol-myers-squibb-bmy-earnings-q3-2024.html


Developed by Leo Phan